SCHEMBL2160894

SCHEMBL2160894

Cn1nc(N)cc1-c1ccccn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.45
ALDH1A1 P00352 3/20 0.45
NPC1 O15118 5/20 0.44
TP53 P04637 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
TSHR P16473 1/20 0.44
LMNA P02545 4/20 0.43
CCR1 P32246 2/20 0.43
CCR5 P51681 2/20 0.43
CCR8 P51685 2/20 0.43
CYP1A2 P05177 1/20 0.43
POLB P06746 1/20 0.43
METAP1 P53582 1/20 0.43
BLM P54132 1/20 0.43
HIF1A Q16665 1/20 0.43
DOHH Q9BU89 1/20 0.43
P4HTM Q9NXG6 1/20 0.43
L3MBTL1 Q9Y468 4/20 0.42
RAB9A P51151 3/20 0.42
MAPT P10636 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13184344 0.82 KDM4E (0.52) KDM4EALDH1A1NPC1TP53SMN1; SMN2
SCHEMBL10513619 0.81 NPC1 (0.46) KDM4EALDH1A1NPC1TP53SMN1; SMN2
SCHEMBL15048557 0.76 PLA2G10 (0.51) KDM4EALDH1A1NPC1TP53SMN1; SMN2
SCHEMBL15048615 0.76 PDE10A (0.42) KDM4EALDH1A1NPC1TP53SMN1; SMN2
SCHEMBL14822776 0.76 PTGS2 (0.54) KDM4EALDH1A1NPC1SMN1; SMN2CYP1A2
SCHEMBL30567673 0.75 KDM4E (0.52) KDM4EALDH1A1NPC1TP53SMN1; SMN2
SCHEMBL2159941 0.75 KDM4E (0.52) KDM4EALDH1A1NPC1TP53SMN1; SMN2
SCHEMBL2013031 0.74 LMNA (0.47) KDM4EALDH1A1NPC1LMNAPOLB
SCHEMBL7371813 0.74 CYP1A2 (0.47) KDM4EALDH1A1NPC1LMNACYP1A2
SCHEMBL22619641 0.73 LMNA (0.46) KDM4EALDH1A1NPC1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2526098-B1 NITROGEN-CONTAINING HETEROARYL DERIVATIVES HOFFMANN LA ROCHE (CH) 2018-07-11 EP claimed
US-8470820-B2 Nitrogen-containing heteroaryl derivatives HOFFMAN-LA ROCHE INC. (US) 2013-06-25 US claimed
EP-2526098-B1 NITROGEN-CONTAINING HETEROARYL DERIVATIVES HOFFMANN LA ROCHE (CH) 2018-07-11 EP disclosed
US-8470820-B2 Nitrogen-containing heteroaryl derivatives HOFFMAN-LA ROCHE INC. (US) 2013-06-25 US disclosed
US-20110183979-A1 NITROGEN-CONTAINING HETEROARYL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-07-28 US disclosed
WO-2011089132-A1 NITROGEN-CONTAINING HETEROARYL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183979-A1 NITROGEN-CONTAINING HETEROARYL DERIVATIVES PDE3A, PDE2A, PDE10A KDM4E 2200/4885ALDH1A1 434/4885NPC1 1325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.